Both Pfizer and Moderna are working on bivalent boosters: vaccines made up of both the old formula and a new one that targets the Omicron BA.4 and BA.5 subvariants of the coronavirus. If the shots meet US Food and Drug Administration standards, they will probably be available as early as September, the FDA says.